Fig. 3

Target modulation on PBMCs by LNA-miR-221 inhibitor. Expression levels of miR-221 and CDKN1B were determined by reverse transcription quantitative PCR (RT‐qPCR) in PBMCs isolated from patients at pre-dose (d1) and 24 h after LNA-miR-221 end treatment (d5). Results are expressed as 2^−△Ct or 2^−△△Ct. A and B show modulation of miR-221 and CDKN1B after LNA-miR-221 treatment (paired sample t test, P < 0.05; 95% CI: 95% confidence interval). In C, Western blotting analysis of PTEN and p27 in representative protein samples extracted from PBMCs of patients before and after treatment. D-P. Individual changes of expression level of miR-221 (D-H) and CDKN1B (I-P) in patients from each cohort treated with LNA-i-miR-221 regimen (unpaired sample t test, P: p-value; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Error bars represent mean ± standard deviation of each sample among triplicates